Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
نویسندگان
چکیده
منابع مشابه
Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
Higher doses of erythropoiesis-stimulating agents (ESAs) contribute to atherothrombotic cardiovascular disease in hemodialysis (HD) patients. Thrombocytosis is associated with increased mortality in ESA-treated HD patients. We investigated variables affecting platelet count and its variability (platelet count increment [Δplatelet count]) in HD patients. This retrospective longitudinal and obser...
متن کاملLow versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
The increased risks of death and adverse events with erythropoiesis-stimulating agent (ESA) therapy targeting a higher hemoglobin level are established. It is uncertain whether the adverse effects of ESA therapy are related to dose and are mitigated when a fixed low ESA dose is used. We conducted a multicenter, prospective randomized open-label, blinded-endpoint (PROBE) trial to evaluate fixed ...
متن کاملResistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
The aim of this study was to evaluate the relationship between arterial microcalcification (AMiC) and erythropoiesis-stimulating agents (ESA) hyporesponsiveness in hemodialysis patients. The presence of AMiC was confirmed by pathologic examination of von Kossa-stained arterial specimens acquired during vascular access surgery. We assessed the ESA hyporesponsiveness index (EHRI), defined as the ...
متن کاملDifferences in Erythrocyte Index and Hyporesponsiveness to Erythropoiesis in Hemodialysis Patients Treated with Different Erythropoiesis-Stimulating Agents
The majority of patients undergoing hemodialysis have anemia due to decreased production of erythropoietin. This condition is referred to as renal anemia, and is a type of normocytic and normochromic anemia. Renal anemia contributes to a worsening of quality of life (QOL) and has a poor prognosis for survival. Clinical use of erythropoiesis-stimulating agents (ESAs) has markedly improved the QO...
متن کاملAssociations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
BACKGROUND We aimed to identify associations between erythroferrone (ERFE), a regulator of hepcidin 25, and biomarkers of erythropoiesis and iron metabolism. We also aimed to determine the effects of erythropoiesis-stimulating agents (ESA), continuous erythropoietin receptor activator (CERA) and darbepoetin-α (DA) on ERFE production in patients on hemodialysis (HD). METHODS Blood samples were...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Nephrology and Renovascular Disease
سال: 2016
ISSN: 1178-7058
DOI: 10.2147/ijnrd.s98196